RANKL expression in stromal/osteoblast cells is abnormally upregulated in osteolytic bone lesions of myeloma patients [10], [11], suggesting that some factors derived from myeloma cells may increase RANKL expression in bone marrow to promote osteolytic bone disease. The gene discussed is TNFSF11; the disease is plasma cell myeloma.